The Innovative Therapies Days will make the connection between the academic and the industrial worlds: from research, to clinical trials, to industrialisation.
CAR-T CELLS, CELL THERAPIES, CELL-DERIVED INNOVATIVE THERAPIES
This session will cover a wide range of topics from cell therapies, like CAR-T cells, to new cell-derived therapies. We will develop the understanding mechanisms and research in this session, including the clinic with feedback from international speakers (Austria, China, Germany, …). Transfers in clinical development will also be discussed.
Mixing and exchanges of people from different backgrounds (academics, scientists, pharmacists, clinicians, mature and young biotech companies…) will provide an excellent platform to help the development of cell and gene therapies in France and worldwide to propose these innovative drugs to patients.
REGULATION, PRODUCTION AND CLINICAL TRANSFER OF INNOVATIVE THERAPIES
This session will highlight the capacity of the University Hospital Center to conduct clinical trials and what issues to anticipate. On this occasion, we will give examples from the regional ecosystem with pre-industrial structures.
We will also talk about the regulatory science and innovation task force by the European Medicines Agency and the guidelines defined for ATMPs in European and America.
WEDNESDAY, OCTOBER 11TH
17:00-21:00 : WELCOME EVENING (BIO INNOVATION)
RIGHT Institute students present scientific posters, visit Bio Innovation and discover the regional bioclust
Thursday, October 12th
8:30 : REGISTRATION AND WELCOME COFFEE (KURSAAL BALLROOM)
9:00 : WELCOME ADRESS AND INTRODUCTION (KURSAAL)
Dr. Sylvain Perruche, RIGHT Institute, Besançon, FR
Laurent Deschamps, PMT President, Besançon, FR
Representative of the President of Grand Besançon Métropole
Representative of the President of the Bourgogne Franche Comté Region
09:20-12:30 : SESSION #1 « UPCOMING INNOVATIVE THERAPIES »
Chairpersons : Dr. Christelle Monville, I-Stem, Evry and Dr. Sylvain Perruche, RIGHT Institute, Besançon, FR
09:20 : CELLS OR SECRETOME FOR THE TREATMENT OF HEART FAILURE ?
Prof. Dr. Philippe Menasché, INSERM U970 – Hôpital Européen Georges Pompidou, Paris, France
09:55 : IMMUNE SECRETOMES TARGETING AGE-ACQUIRED IMMUNE DECLINE
Dr. Hans Keirstead, Immunis, Irvine, USA
10:30 : BREAK – EXHIBITION HALL
11:15 : THE CLINICAL TRANSLATION OF ST266, A NOVEL AMNION CELL-DERIVED SECRETOME
Dr. Larry Brown, Noveome Biotherapeutics, Pittsburg, USA
11:45 : MACROPHAGE THERAPY FOR LIVER DISEASES, TITLE TO BE ANNOUNCED
Dr. Victor Dillard, Resolution Therapeutics, Edinburgh, UK
12:15-14:00 : LUNCH
13:00-14:30 : Exhibition Hall – B2B MEETINGS
14:00-14:30 : EFS SYMPOSIUM
Selected oral presentation from PhD students from the RIGHT Institute, Besançon, FR
14:30-18:00 : SESSION #2 “CAR TECHNOLOGY: FROM CAR-T TO CAR-NK”
Chairpersons: Dr. Marina Deschamps and Dr. Christophe Ferrand, RIGHT institute, Besançon, FR
14:30 :ALLOGENEIC CAR T-CELLS FOR ADOPTIVE CELL THERAPY
Dr. Mark Frattini, Cellectis, New-York, USA
15:00 : HIGH EFFECTIVENESS AND SAFETY OF ANTI-CD7 CAR T-CELL THERAPY IN TREATING RELAPSED OR REFRACTORY (R/R) T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL)
Peihua (Peggy) Lu, MD, Lu Daopei Hospital and Beijing Lu Daopei Institute of Hematology, China
15:30 : ENABLING MANUFACTURING OF GENE-EDITING CELL THERAPIES
Dr. Mélanie Rietenbach, Miltenyi Biotech, Düsseldorf, Germany
16:00 : BREAK – EXHIBITION HALL
16:45 : DEVELOPMENT OF ALLOGENEIC CAR-T CELLS BASED ON T CELL PROGENITORS
Dr. Olivier Negre, Smart Immune, Paris, France
17:15 : NATURAL KILLER CELLS – ENGINEERED TO BEAT CANCER
Dr. Ralph Brandenberger, Nkarta Therapeutics, San Francisco, USA
18:00-19:30 : B2B MEETINGS OR VISIT OF BESANÇON
19:30 : COCKTAIL
(on registration only)
20:00 : EVENING RECEPTION
(on registration only)
Friday, October 13th
8:30 : WELCOME COFFEE
08:30-09:15 : EXHIBITION HALL – B2B MEETINGS
09:15 – 12:00 : SESSION #3 “PATHWAYS FOR INNOVATIVE THERAPIES”
Chairpersons :Dr.Olivier Humbey, IQVIA, Dijon and Dr. Mathieu Guerriaud, CREDIMI, Dijon, FR
09:15 : PIPELINE ANALYSIS OF CELL AND GENE THERAPY PRODUCTS
Dr. Gavin Yirajen Vuddamalay, Mabdesign, Lyon, France
09:45 : EU SUPPORT AND INCENTIVES FOR INNOVATIVE DRUG DEVELOPMENT: OVERVIEW OF THE REGULATORY ADVICE TOOLBOX AND TREND ANALYSIS
Dr. Oriane Blanquie, European Medicines Agency, Amsterdam, Netherlands
10:15 : BREAK- EXHIBITION HALL
11:00 : HOW CAN CELL AND GENE THERAPIES OVERCOME CURRENT MARKET ACCESS CHALLENGES TO DELIVER ON THEIR PROMISE ?
Dr. Christopher Ball, IQVIA, London, UK
11:30 : DIGITAL SOLUTIONS TO SECURE YOUR BIOPROCESS: EFFICIENT FACILITY DESIGN AND ACCELERATED OPERATOR COMPETENCY – A RD-BIOTECH CASE STUDY
Kajsa Löwenhielm, Cytiva, Amersham, UK and Dr. Jean-Luc Schlick, RD-Biotech, Besançon, FR
12:00-14:00 : LUNCH
12:40-14:00 : Exhibition Hall – B2B MEETINGS
14:00-16:30 : SESSION #4 “CELL AND GENE THERAPIES”
Chairpersons :Dr. Fanny Delettre, EFS,andDr. Jean-Luc Schlick, RD-Biotech, Besançon, FR
14:00 : OVERVIEW OF CELL AND GENE THERAPY IN ANIMAL HEALTH
Dr. Michael Donabedian, Vetoquinol, Lure, France
14:30 : HOSPITAL EXEMPTION AS ALTERNATIVE TO SUCCEED IN ATMPS DEVELOPMENT : THE EXAMPLE OF THE ADICROHN PROJECT
Dr. Jérémy Magalon, AP-HM, Marseille, France
15:00 : BREAK – EXHIBITION HALL
15:30 : RETINAL PIGMENT EPITHELIAL CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS DISPOSED ON HUMAN AMNIOTIC MEMBRANE: AN UPDATE ON THE FRENCH RP CLINICAL TRIAL
Dr. Christelle Monville, I-Stem, Evry, France
16:00 : HUMAN CD34+ CELLS FOR THE TREATMENT OF ACUTE ISCHEMIC STROKE
Dr. Ibon Garitaonandia, CellProthera, Mulhouse, France
16:30-16:45 : CONCLUSION END OF CONGRESS
Dr. Christophe Ferrand, RIGHT Institute, Besançon, FR
Renaud Gaudillière, PMT director, Besançon, FR
16:45–17:45 : B2B MEETINGS
16:45-18:00 : BEER PARTY
